APA (7th ed.) Citation

K, S., T, G., R, N., M, K., H, U., M, M., . . . S, Y. (2025). Second-line anti-CD38 monoclonal antibody therapy mitigates the negative impact of functional high-risk status in myeloma patients. International journal of hematology, 121(6), 801. https://doi.org/10.1007/s12185-025-03941-1

Chicago Style (17th ed.) Citation

K, Suzuki, et al. "Second-line Anti-CD38 Monoclonal Antibody Therapy Mitigates the Negative Impact of Functional High-risk Status in Myeloma Patients." International Journal of Hematology 121, no. 6 (2025): 801. https://doi.org/10.1007/s12185-025-03941-1.

MLA (9th ed.) Citation

K, Suzuki, et al. "Second-line Anti-CD38 Monoclonal Antibody Therapy Mitigates the Negative Impact of Functional High-risk Status in Myeloma Patients." International Journal of Hematology, vol. 121, no. 6, 2025, p. 801, https://doi.org/10.1007/s12185-025-03941-1.